脂质体-鱼精蛋白-DNA复合物的制备及对树突状细胞的成熟诱导

目的研究脂质体-鱼精蛋白-DNA复合物(LPD)的制备方法及对树突状细胞(DC2.4)的成熟诱导作用。方法薄膜-超声分散法制备空白的阳离子脂质体,再与鱼精蛋白-DNA复合物室温孵育形成LPD;测定其粒径和电位。流式细胞仪检测鼠源树突状细胞系DC2.4的甘露糖受体表达水平;用DC2.4表面标记分子CD80、CD40、CD86和MHC-2的表达水平,考查LPD对树突状细胞的成熟诱导作用。结果 LPD的最佳比例为DDAB-鱼精蛋白-DNA(2∶1.5∶1);LPD粒径为84.28±0.56 nm,Zeta电位为27.33±1.23 mV。通过FITC-ManBSA的结合作用检测到DC2.4表面有83%的甘露糖受体表达。LPD明显上调DC2.4表面标记分子的表达水平(P<0.05)。结论 LPD制备工艺简单,是一个良好的疫苗佐剂。     

Cytodext-3微载体/藻酸钠水凝胶作为可注射性支架构建组织工程软骨的可行性

BACKGROUND: Alginate hydrogel and microcarrier both can be used as injectable scaffolds, but their shortcomings such as poor mechanical property and poor plasticity remain unresolved. OBJIECTIVE: To explore the feasibility of constructing an injectable tissue-engineered cartilage with cytodex-3 microcarrier/alginate hydrogel composite. METHODS: Injectable cytodex-3 microcarrier/alginate hydrogel composite scaffold and injectable alginate hydrogel scaffold were established, and the mechanical properties of the two scaffolds were detected. Chondrocytes-seeded cytodex-3 microcarrier was obtained after incubated in the bioreactor, and then composited with alginate hydrogel as experimental group; chondrocytes were co-cultured with alginate hydrogel as control group. Subsequently, cell viability and ability of DNA and glycosaminoglycan synthesis were detected. RESULTS AND CONCLUSION: The Young’s modulus of the experimental group was significantly higher than that of the control group (P < 0.05). And in the control group, chondrocytes were in a round shape and evenly distributed in the alginate hydrogel; in the experimental group, chondrocytes adhered on the scaffold surface and evenly distributed in the scaffold. After 1 day of culture, both viable and numerous dead chondrocytes could be found in both two scaffolds; and after 14-day culture, there were no dead chondrocytes in both two scaffolds, abundant proliferating chondrocytes maintained a high cell viability, and the number of chondrocytes in the experimental group was significantly higer than that of the control group. What’s more, the contents of DNA and glycosaminoglycans were in a rise with time in both two groups, which were significantly higher in the experimental group than the control group (P < 0.05). These results suggest that the cytodex-3 microcarrier/alginate hydrogel composite is a promising injectable scaffold in cartilage tissue engineering.     

升清胶囊对阻塞性黄疸患者微创术后细胞免疫功能的改善作用

目的 研究升清胶囊对阻塞性黄疸患者微创术后细胞免疫功能的改善作用.方法 将符合纳入标准的51例患者,采用简单随机方法分为研究组(升清胶囊组)、对照组(胆维他组)和空白组(常规治疗组),每组17例.术后空白组常规处理,不服用利胆药物;对照组除常规处理外,于术后第1天起口服胆维他;研究组除常规处理外,于术后第1天开始口服中药升清胶囊.术后第1、7天分别检测患者免疫指标CD3、CD4、sIL-2R、IL-10、TNF及TB.采用单因素方差分析的统计学方法对实验数据做统计处理.结果 研究组、对照组与空白组术后第1天CD3、CD4、sIL-2R、TNF、IL-10值比较均无统计学差异(P>0.05);术后第7天比较均有统计学差异(P<0.05).术后第7天CD.CD4、sIL-2R值与术后第1天比较,研究组比对照组均增高(P<0.05);时照组比空白组均增高(P<0.05);研究组比空白组均增高(P<0.05).术后第7天TNF值与术后第1天比较,研究组较对照组无显著性降低(P>0.05);对照组比空白组降低(P<0.05);研究组比空白组降低(P<0.05).术后第7天IL-10值与术后第1天比较,研究组比对照组降低(P<0.05);对照组比空白组无显著性降低(P>0.05);研究组比空白组降低(P<0.05).术后第1、7天各组间TB值比较均无统计学差异(P>0.05).结论 升清胶囊能更有效地加快阻塞性黄疸患者微创术后免疫功能的恢复,较不服用利胆药物及服用胆维他者有明显优势.     

转运体介导的肾靶向雷公藤内酯醇前体药物TPS-L-Carnitine的合成及体外细胞摄取研究

【摘要】 目的 研究有机阳离子转运体(OCN2)介导的肾靶向雷公藤内酯醇(P)前体药物P丁二酸酯(P)-L-肉毒碱(P-L-Carnitine)的合成方法和体外靶向细胞摄取。方法 将P与丁二酸酐在碱性条件下生成P,再与L-肉毒碱成酯得前体药物P-L-Carnitine, 利用OCN2对L-肉毒碱的特异性识别和结合,使前药主动靶向到肾近端小管上皮细胞。初步研究不同温度、浓度以及竞争抑制剂存在时人近端小管上皮细胞株K-2细胞对前药和母体药物的摄取。结果 K-2细胞对前药的吸收可饱和,具有温度和浓度依赖性,可被竞争抑制剂抑制,37 ℃相同给药浓度时, 细胞对P-L-Carnitine的摄取明显多于P,证实细胞对P-L-Carnitine的摄取机制是通过转运体介导的内吞作用。结论 P-L-Carnitine具有良好的肾靶向性,为进一步体内肾靶向研究奠定了基础。     

急性脑梗死溶栓治疗院内延迟的影响因素研究

目的 研究脑梗死患者从到达医院到开始正确治疗的时间(院内延迟),分析导致延迟的相关因素及对策.方法 回顾性研究了进入医院就诊的急性脑梗死患者的院内延迟情况及其影响因素.结果 院内延迟中位数时间为66 min,60 min内接受治疗者68例(60.71%).单因素分析显示院内延迟与下列变量之间关系密切:无常见病因,成人,首发症状为传统症状,由120救护车进行运送.性别及有、无医疗保险对院内延迟无显著影响.多因素回归模型显示仅常见病因的有无、年龄、首发症状以及运送方式与院内延迟有明显相关性.结论 急性脑梗死患者院内延迟严重阻碍超早期溶栓治疗,需进一步提高医生脑梗死诊治水平;加强急救系统建设,尽可能使脑梗死患者使用急救车转运至医院. Abstract： Objective To study the causes of hospital delays of thrombolysis in our hospital.Methods We prospectively studied the hospital delay of acute cerebral infarction(ACI)patients in our hospital and establish some countermeasures.Results The hospital delay time for all patients was 66(34～82)minutes.The present study shows that 68 patients(60.71%)accepted thrombolysis within 60 minutes after arrival. Univariate analysis showed that the reason of the hospital delays:no common cause of disease,adult,traditional symptoms of stroke and 120 ambulance transportation.Sex,medical insurance had no significant effect on early treatment.A multivariate regression model demonstrated that the most significant factors associated with early treatment were having or no common cause of disease,age,methods of transportation and type of symptoms of stroke.Conclusions Hospital delays of ACI patients have a significant influence on the effect of thrombdysis in superacute stage.To reduce the hospital delay time,doctors' professional ability should be improved.And also,it is necessary to improve emergency system, reduce transportation time.